Gigi Zheng, MD, PhD

Moderna, Inc.

Disclosure(s): ModernaTX: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-517) Symptom Severity and Functional Impact of Medically-Attended Influenza, SARS-CoV-2 and RSV Illnesses among Children
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-669) Comparing Influenza, SARS-CoV-2, and RSV Illnesses among Adults with and without Chronic Medical Conditions
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-670) Absenteeism due to Viral Acute Respiratory Infections in Children, 2024-2025
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-1592) Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged ≥ 18 years in the United States
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET

• (P-1644) Real-World Effectiveness of Moderna’s mRNA-1273 COVID-19 Vaccine Across Multiple Seasons and Variant Periods in the United States
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET